HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia.

Abstract
Adult T-cell leukemia-lymphoma (ATL) is an aggressive peripheral T-cell neoplasm that develops after long-term infection with the human T-cell leukemia virus-1 (HTLV-1). HTLV-1-specific cytotoxic T lymphocytes (CTLs) play an important role in suppressing proliferation of HTLV-1-infected or transformed T-cells in vitro. Efficient induction of antigen-specific CTLs is important for immunologic suppression of oncogenesis, but has evaded strategies utilizing poorly immunogenic free synthetic peptides. In the present study, we examined the efficient induction of HTLV-1-specific CD8+ T-cell response by an HTLV-1/hepatitis B virus core (HBc) chimeric particle incorporating the HLA-A*0201-restricted HTLV-1 Tax-epitope. The immunization of HLA-A*0201-transgenic mice with the chimeric particle induced antigen-specific gamma-interferon reaction, whereas immunization with epitope peptide only induced no reaction as assessed by enzyme-linked immunospot assay. Immunization with the chimeric particle also induced HTLV-1-specific CD8+ T-cells in spleen and inguinal lymph nodes. Furthermore, upon exposure of dendritic cells from HLA-A*0201-transgenic mice to the chimeric particle, the expression of CD86, HLA-A02, TLR4 and MHC class II was increased. Additionally, our results show that HTLV-1-specific CD8+ T-cells can be induced by peptide with HTLV-1/HBc particle from ATL patient, but not by peptide only and these HTLV-1-specific CD8+ T-cells were able to lyse cells presenting the peptide. These results suggest that HTLV-1/HBc chimeric particle is capable of inducing strong cellular immune responses without adjuvants via effective maturation of dendritic cells and is potentially useful as an effective carrier for therapeutic vaccines in tumors, or in infectious diseases by substituting the epitope peptide.
AuthorsTomohiro Kozako, Katsuhiko Fukada, Shinya Hirata, Yohann White, Michiko Harao, Yasuharu Nishimura, Youichiro Kino, Shinji Soeda, Hiroshi Shimeno, François Lemonnier, Shunro Sonoda, Naomichi Arima
JournalMolecular immunology (Mol Immunol) Vol. 47 Issue 2-3 Pg. 606-13 (Dec 2009) ISSN: 1872-9142 [Electronic] England
PMID19889459 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adjuvants, Immunologic
  • Gene Products, tax
Topics
  • Adjuvants, Immunologic (pharmacology)
  • Amino Acid Sequence
  • Base Sequence
  • Cell Differentiation (drug effects)
  • Cytotoxicity, Immunologic (drug effects)
  • Dendritic Cells (cytology, drug effects, immunology)
  • Gene Products, tax (immunology)
  • Hepatitis B virus (immunology)
  • Heterozygote
  • Human T-lymphotropic virus 1 (immunology)
  • Humans
  • Immunity, Cellular (drug effects, immunology)
  • Immunization
  • Injections, Intradermal
  • Leukemia-Lymphoma, Adult T-Cell (immunology, prevention & control)
  • Molecular Sequence Data
  • Species Specificity
  • T-Lymphocytes, Cytotoxic (cytology, drug effects, immunology)
  • Virion (chemistry, genetics, immunology, ultrastructure)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: